Xuanzhu Bio-B(02575): The Hong Kong Stock Exchange has approved the application to implement the full circulation of H shares.
Xuanzhu Biology-B (02575) announced that on April 16, 2026, the Stock Exchange approved the listing and trading of 357 million H shares. However, the conversion and listing of all other conditions must be met before it can take effect.
Xuanzhu Bio-B (02575) announced that on April 16, 2026, the Hong Kong Stock Exchange approved the listing and trading of 357 million H shares (based on the proposed full circulation and conversion of H shares and the conversion of non-listed shares for listing), subject to the fulfillment of all other conditions for conversion and listing before it can be implemented.
Related Articles
New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.
New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.
Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
New stock news | Fylaland submits application to Hong Kong Stock Exchange for China's largest smart pool equipment supplier.
New stock news | Capital (601136.SH) submits a second application to the Hong Kong Stock Exchange, with total revenue exceeding 3.6 billion yuan in 2025.
Jiangsu Kanion Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of Qingcan Tongluo Granules.
RECOMMEND
Hong Kong Hard‑Tech Companies Enhance Canton Fair Presence As Veterans And Newcomers Expand International Networks
17/04/2026
Thousand‑Fold Oversubscription In Hong Kong IPOs Signals Multiple Market Shifts
17/04/2026
Rising Compute Costs Drive Industry Price Increases As Institutions Expect Internet Firms To Outperform In Q1
17/04/2026
